Antineoplastics
1
Reactions 1354 - 4 Jun 2011 Antineoplastics Various toxicities: 3 case reports Three women with metastatic breast cancer developed various toxicities while receiving bevacizumab combined with either paclitaxel, capecitabine [Xeloda] or docetaxel [routes, durations of therapy to reactions onset and patient outcomes not stated]. In April 2008, a 55-year-old woman commenced docetaxel 75 mg/m 2 and bevacizumab 15 mg/kg on day 1 every 3 weeks as part of a clinical trial. She reported fatigue, nausea, hoarseness, arthralgia, alopecia and mucositis. In November 2008, docetaxel was withdrawn after 12 cycles of treatment due to asthenia. Bevacizumab was continued with capecitabine 3000 mg/day on days 1–14 every 3 weeks. She then developed erythrodysaesthesia, onycholysis and asthenia. In April 2009, her capecitabine dosage was reduced by 25% after seven cycles due to erythrodysaesthesia. In August 2009, she was removed from the trial due to disease progression. A 44-year-old woman was enrolled in the Avastin Therapy for Advanced Breast Cancer (ATHENA) trial and started receiving bevacizumab [dosage not stated] and paclitaxel in May 2008. By November 2008, she had completed 14 cycles of treatment. She then received monotherapy with bevacizumab until May 2009 (total of 26 cycles). Bevacizumab was then discontinued and her participation in the trial ended. While receiving bevacizumab, she developed slightly increased BP, intermittent exanthema and occasional headaches, for which she received paracetamol [acetaminophen]. She then received capecitabine and pamidronic acid, which was well-tolerated. A woman, diagnosed with breast cancer at 30 years of age, underwent mastectomy in September 2005. She was enrolled in the ATHENA trial and started receiving bevacizumab 10 mg/kg every 2 weeks and paclitaxel 90 mg/m 2 /week with bisphosphonates in November 2007. During treatment, she developed dizziness, fatigue, high BP, neurotoxicity and hoarseness. She also experienced urinary frequency and a single episode of mucositis during her fourth cycle of bevacizumab. Paclitaxel was discontinued in April 2008 (after six cycles). She received bevacizumab with bisphosphonates until February 2009, during which she had mild epistaxis, dizziness and persistent asthenia. Her neurotoxicity resolved in June 2008. In February 2009, she reported increasing asthenia. After discovery of an indwelling device-associated thrombosis, she was admitted for 1 month and bevacizumab treatment was stopped. Despite hepatic disease relapse, she refused further chemotherapy and subsequently received letrozole and a LHRH receptor agonist in April 2009. Ferreira A, et al. Bevacizumab in the treatment of metastatic breast cancer: Three case reports. Current Opinion in Oncology 23: S11-S19, Apr 2011. Available from: URL: http://dx.doi.org/10.1097/01.cco.0000397418.52374.28 - Portugal 803054845 1 Reactions 4 Jun 2011 No. 1354 0114-9954/10/1354-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics
Reactions 1354 - 4 Jun 2011
Antineoplastics
Various toxicities: 3 case reportsThree women with metastatic breast cancer developed
various toxicities while receiving bevacizumab combinedwith either paclitaxel, capecitabine [Xeloda] or docetaxel[routes, durations of therapy to reactions onset and patientoutcomes not stated].
In April 2008, a 55-year-old woman commenceddocetaxel 75 mg/m2 and bevacizumab 15 mg/kg onday 1 every 3 weeks as part of a clinical trial. She reportedfatigue, nausea, hoarseness, arthralgia, alopecia andmucositis. In November 2008, docetaxel was withdrawnafter 12 cycles of treatment due to asthenia. Bevacizumabwas continued with capecitabine 3000 mg/day ondays 1–14 every 3 weeks. She then developederythrodysaesthesia, onycholysis and asthenia. In April2009, her capecitabine dosage was reduced by 25% afterseven cycles due to erythrodysaesthesia. In August 2009,she was removed from the trial due to disease progression.
A 44-year-old woman was enrolled in the AvastinTherapy for Advanced Breast Cancer (ATHENA) trial andstarted receiving bevacizumab [dosage not stated] andpaclitaxel in May 2008. By November 2008, she hadcompleted 14 cycles of treatment. She then receivedmonotherapy with bevacizumab until May 2009 (total of26 cycles). Bevacizumab was then discontinued and herparticipation in the trial ended. While receivingbevacizumab, she developed slightly increased BP,intermittent exanthema and occasional headaches, forwhich she received paracetamol [acetaminophen]. Shethen received capecitabine and pamidronic acid, which waswell-tolerated.
A woman, diagnosed with breast cancer at 30 years ofage, underwent mastectomy in September 2005. She wasenrolled in the ATHENA trial and started receivingbevacizumab 10 mg/kg every 2 weeks and paclitaxel90 mg/m2/week with bisphosphonates in November 2007.During treatment, she developed dizziness, fatigue, highBP, neurotoxicity and hoarseness. She also experiencedurinary frequency and a single episode of mucositis duringher fourth cycle of bevacizumab. Paclitaxel wasdiscontinued in April 2008 (after six cycles). She receivedbevacizumab with bisphosphonates until February 2009,during which she had mild epistaxis, dizziness andpersistent asthenia. Her neurotoxicity resolved in June2008. In February 2009, she reported increasing asthenia.After discovery of an indwelling device-associatedthrombosis, she was admitted for 1 month andbevacizumab treatment was stopped. Despite hepaticdisease relapse, she refused further chemotherapy andsubsequently received letrozole and a LHRH receptoragonist in April 2009.Ferreira A, et al. Bevacizumab in the treatment of metastatic breast cancer: Threecase reports. Current Opinion in Oncology 23: S11-S19, Apr 2011. Available from:URL: http://dx.doi.org/10.1097/01.cco.0000397418.52374.28 -Portugal 803054845
1
Reactions 4 Jun 2011 No. 13540114-9954/10/1354-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
